Key Highlights

  • Quarterly Net Income reached USD 1,166.2 million, or USD 9.65 for each diluted share, a sharp turnaround from a USD 40.7 million loss, or USD 0.39 a share, in the prior-year period.
  • A gain of about USD 1,348.1 million from selling sevasemten to Servier powered the swing, even though the operating loss stood at USD 46.1 million for the period.
  • The company held USD 1,743.9 million across cash, equivalents and marketable securities on September 30, 2026, enough, management said, for planned spending over at least 12 months.
  • Research spending dropped to USD 31.6 million from USD 37.5 million, whereas general and administrative outlays grew to USD 14.6 million from USD 9.4 million.

Servier Transaction Turns the Quarter Positive

Edgewise Therapeutics (NASDAQ:EWTX) published its Quarterly Report on November 4, 2026. The company logged USD 1,166.2 million of net income after a USD 40.7 million loss in Q3 2025. Nine-month net income reached USD 1,059.8 million. The turnaround stems from completing, on July 10, 2026, the sale of sevasemten and its muscular dystrophy program to Servier. Upfront consideration totaled USD 1,396.1 million, with USD 153.9 million held in escrow, bringing expected initial proceeds to USD 1,550.0 million, and up to USD 1,100.0 million in milestones may follow. Tax expense of USD 155.3 million was booked against the gain, converting pretax income of USD 1,321.5 million into the reported net figure. The share count stood at 109,457,922 on September 30, 2026.

Underlying Operating Shortfall Remains Visible

Management noted that, excluding the gain, significant losses are expected to continue. Operating losses hit USD 46.1 million in the quarter, roughly flat against USD 46.9 million, and reached USD 162.2 million for nine months versus USD 135.4 million. Interest income reached USD 16.5 million, compared with USD 6.2 million, because the cash balance grew. Other income of USD 3.1 million came from transition services provided to Servier. Operating cash outflow was USD 163.3 million over nine months, and Retained Earnings closed the quarter at USD 513.4 million. Diluted EPS of USD 9.65 sits below basic EPS of USD 10.71, reflecting roughly 120.9 million diluted weighted shares against about 108.9 million basic. The extract does not split that operating loss by program.

Cardiac Pipeline Shifts Toward a Phase 3 Start

Edgewise now calls itself a cardiovascular-focused clinical-stage biopharmaceutical company. Its lead candidate, EDG-7500, is an oral cardiac sarcomere modulator. A June 2026 announcement reported top-line results from a 12-week study in hypertrophic cardiomyopathy, and a Phase 3 start is planned for the fourth quarter of 2026. EDG-15400, the second candidate, is in a Phase 2 study targeting heart failure with preserved ejection fraction. Spending on research is expected to climb sharply, the company notes, and it warns that development is inherently uncertain, with timing and cost impossible to predict precisely, so the schedule for these studies remains open.

Where Things Stand

No, the quarter's profit does not reflect ongoing earnings power. Edgewise Therapeutics (NASDAQ:EWTX) booked USD 1,166.2 million of net income largely because of a sale gain, whereas the USD 46.1 million operating loss reveals what the Business spends before that item. Holdings of USD 1,743.9 million provide a runway for the pipeline, and that runway matters more than the one-time profit. Watch the fourth-quarter EDG-7500 Phase 3 start and any Servier milestone payments. Revenue is absent from the filing, and the extract has no share price move.